Nautilus Biotechnology, Inc. (NAUT) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 3 recommend buying, 1 recommend holding, and 1 recommend selling.
The analyst consensus price target for NAUT is $2.50, representing a -18.3% downside from the current price of $3.06. Price targets range from a low of $2.50 to a high of $2.50.
